Androstenedione, a key biomarker in endocrinology, holds significant importance in understanding hormonal physiology and clinical implications. This steroid hormone is synthesized primarily in the adrenal glands and gonads and serves as a precursor to major sex hormones, including testosterone and estrogen.
Its pivotal role in hormone production underscores its relevance in various physiological processes, ranging from sexual development and reproductive health to metabolism and immune function.
In clinical practice, assessing androstenedione levels provides valuable insights into adrenal and gonadal function, aiding in the diagnosis and management of conditions such as polycystic ovary syndrome (PCOS), adrenal insufficiency, and androgen excess disorders.
Understanding the physiological significance and clinical implications of androstenedione is paramount for healthcare providers in effectively evaluating hormonal status and guiding patient care. This article aims to provide a comprehensive overview of androstenedione, its role in endocrinology, and its relevance in clinical practice.
Androstenedione, a steroid hormone belonging to the androgen group, is a precursor to testosterone and estrogen.
It features a four-ring carbon structure with 19 carbon atoms characterized by modifications at various positions that influence its biological activity. This hormone plays a pivotal role in the synthesis of other steroid hormones, serving as a precursor in the production of both androgens and estrogens in the body.
Androstenedione is primarily synthesized in the adrenal glands and gonads. In the adrenal glands, cholesterol is converted into pregnenolone, which undergoes subsequent transformations into DHEA or 17-OH progesterone and then to androstenedione.
Similarly, in the gonads, the conversion of cholesterol to androstenedione occurs through various enzymatic steps.
Once synthesized, androstenedione can be further metabolized into testosterone in peripheral tissues such as the liver, adipose tissue, and skin, or aromatized into estrone in adipose tissue.
Androstenedione exerts various physiological functions, primarily related to its role as a precursor to sex hormones.
As a precursor to testosterone, it plays a role in the development of secondary sexual characteristics, muscle mass maintenance, and libido.
Androstenedione also serves as a precursor to estrogen, the primary female sex hormone, which is essential for reproductive health, bone density regulation, and cardiovascular function.
The balanced production of androstenedione is crucial for maintaining hormonal homeostasis and overall health in both males and females.
As a vital precursor in the synthesis of sex hormones, primarily testosterone and estrogen, androstenedione has many clinical implications.
Once produced from DHEA or 17-OH progesterone, androstenedione can then be converted estrone or testosterone: each pathway has distinct clinical implications.
In males, androstenedione contributes to the production of testosterone, which is essential for the development and maintenance of male reproductive organs, secondary sexual characteristics, and overall reproductive function. In females, androstenedione can be converted into testosterone in peripheral tissues, contributing to androgen production and influencing various aspects of reproductive health, including libido and ovarian function.
Moreover, androstenedione can be aromatized into estrogen, playing a crucial role in female reproductive processes, bone health, and cardiovascular function.
Maintaining a balance of estrogen and testosterone is essential for male and female health and hormone balance. If one pathway is favored over another, functional hormone imbalance and associated symptoms can occur.
Androstenedione levels hold clinical significance in evaluating adrenal and gonadal function. Elevated levels of androstenedione may indicate disorders such as adrenal hyperplasia, adrenal tumors, or ovarian dysfunction. Conversely, decreased levels of androstenedione may be observed in conditions such as adrenal insufficiency or hypogonadism. [8.]
Assessing androstenedione levels along with other adrenal and gonadal hormones aids in diagnosing and monitoring various endocrine disorders and guiding appropriate treatment interventions.
Androstenedione levels are closely linked to conditions affecting adrenal and ovarian function, such as polycystic ovary syndrome (PCOS) and adrenal disorders.
In PCOS, elevated androstenedione levels contribute to androgen excess which causes symptoms such as hirsutism, acne, menstrual irregularities, and infertility. Similarly, adrenal disorders such as congenital adrenal hyperplasia (CAH) or adrenal tumors can result in abnormal androstenedione production, leading to clinical manifestations such as virilization and adrenal insufficiency. [6., 8., 9.]
Androstenedione has gained popularity as a performance-enhancing supplement due to its purported ability to increase testosterone levels and promote muscle growth and athletic performance. However, the use of androstenedione as a supplement is controversial and potentially risky. [4.]
Long-term use of androstenedione may lead to hormonal imbalances, adverse cardiovascular effects, cancer, liver toxicity, and suppression of natural hormone production. Additionally, its classification as a prohormone raises concerns regarding its legality and regulation in sports and competitive settings. [5.]
Healthcare providers should counsel patients on the potential risks associated with androstenedione supplementation and encourage safer and evidence-based approaches to enhancing athletic performance.
Androstenedione levels are most commonly measured in blood or urine samples. Immunoassays, such as enzyme-linked immunosorbent assays (ELISA), are frequently employed due to their sensitivity and specificity in detecting and quantifying androstenedione levels. These assays utilize specific antibodies that bind to androstenedione molecules, allowing for accurate measurement.
Gas chromatography-mass spectrometry (GC-MS) is another reliable method used for its precise quantification, particularly in research settings or when high accuracy is required.
LC-MS/MS (liquid chromatography-tandem mass spectrometry) has also gained popularity for its ability to provide highly sensitive and specific measurements, making it suitable for clinical diagnostics and research purposes alike.
Blood and urine testing for androstenedione offer distinct advantages and limitations, making each method suitable for specific clinical scenarios.
Blood Testing
Blood testing offers some distinct benefits: it provides a direct measurement of circulating androstenedione levels, offering a snapshot of the hormone's concentration in the bloodstream at a given moment. Blood tests have also been extensively validated in clinical settings, making them reliable for diagnostic purposes.
However, blood tests are relatively invasive.
Reference Ranges:
Reference ranges vary by lab, but common serum reference ranges include:
Female, 1 to 10 years: 8-50 ng/dL (0.3-1.7 nmol/L)
Female, 10 to 17 years: 8-240 ng/dL (0.3-8.4 nmol/L)
Adult female: 85-275 ng/dL (3-9.6 nmol/L)
Adult male: 75-205 ng/dL (2.6-7.2 nmol/L)
Urine Testing
Urine collection is non-invasive and relatively easy, and generally reflects plasma levels. [1.] It is generally not required for diagnosis but may be helpful to confirm certain diagnoses. Hydration status, renal function, and medication use, can all affect the accuracy of test results.
Interpretation of androstenedione test results depends on various factors, including the patient's age, sex, and medical history. Elevated levels of androstenedione may indicate conditions such as polycystic ovary syndrome (PCOS), congenital adrenal hyperplasia (CAH), adrenal tumors, or ovarian tumors. In females, elevated androstenedione levels can lead to symptoms such as hirsutism, acne, and menstrual irregularities.
Conversely, low levels of androstenedione may be associated with adrenal insufficiency or adrenal gland dysfunction. It's crucial to correlate test results with clinical symptoms and other hormonal markers for accurate diagnosis and appropriate management.
Monitoring androstenedione levels are indicated in various clinical scenarios to aid in the diagnosis, management, and monitoring of certain endocrine disorders.
For instance, in women presenting with symptoms of hyperandrogenism such as hirsutism, acne, or menstrual irregularities, measuring androstenedione levels can help identify underlying causes such as PCOS or adrenal disorders.
In men, monitoring androstenedione levels may be useful in assessing testicular function or evaluating androgen deficiency disorders. Additionally, monitoring androstenedione levels may be part of the follow-up protocol for patients undergoing treatment for conditions affecting androgen production or metabolism, such as CAH or adrenal tumors, to assess treatment efficacy and disease progression.
[1.] Andino N, James VH, Parker V, Rippon AE. Excretion of non-conjugated androstenedione and testosterone in human urine. Steroids. 1976 Dec;28(6):837-46. doi: 10.1016/0039-128x(76)90034-9. PMID: 189467.
[2.] Antoniou-Tsigkos A, Zapanti E, Ghizzoni L, et al. Adrenal Androgens. [Updated 2019 Jan 5]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278929/
[3.] Badawy MT, Sobeh M, Xiao J, Farag MA. Androstenedione (a Natural Steroid and a Drug Supplement): A Comprehensive Review of Its Consumption, Metabolism, Health Effects, and Toxicity with Sex Differences. Molecules. 2021 Oct 14;26(20):6210. doi: 10.3390/molecules26206210. PMID: 34684800; PMCID: PMC8539210.
[4.] Basaria S. Androgen abuse in athletes: detection and consequences. J Clin Endocrinol Metab. 2010 Apr;95(4):1533-43. doi: 10.1210/jc.2009-1579. Epub 2010 Feb 5. PMID: 20139230.
[5.] FDA Warns Manufacturers To Stop Distributing Products Containing “Andro.” ScienceDaily. Published 2024. Accessed February 26, 2024. https://www.sciencedaily.com/releases/2004/03/040323075302.htm
[6.] Pignatelli D, Pereira SS, Pasquali R. Androgens in Congenital Adrenal Hyperplasia. Front Horm Res. 2019;53:65-76. doi: 10.1159/000494903. Epub 2019 Sep 9. PMID: 31499506.
[7.] Tietz NW (Ed): Clinical Guide to Laboratory Tests, 3rd ed. W. B. Saunders, Philadelphia, PA, 1995.
[8.] Wei R, Bowers K, Kroner GM, Payto D, Colón-Franco JM. The Androstenedione Roche Elecsys immunoassay has superior comparability to the LC-MS/MS assay than the Siemens Immulite immunoassay. Pract Lab Med. 2022 May 10;31:e00279. doi: 10.1016/j.plabm.2022.e00279. PMID: 35620064; PMCID: PMC9127399.
[9.] Yesiladali M, Yazici MGK, Attar E, Kelestimur F. Differentiating Polycystic Ovary Syndrome from Adrenal Disorders. Diagnostics (Basel). 2022 Aug 24;12(9):2045. doi: 10.3390/diagnostics12092045. PMID: 36140452; PMCID: PMC9498167.